Study guide

3.6 Infusion Monitoring & Acute Reaction Differential Management

Transplantation and Cellular Therapy Certified Nurse TCTCN

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy

2 Chapter 2: Foundations of Transplantation & Cellular Biology

2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum

3 Chapter 3: Product Collection, Processing & Infusion Procedures

3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking

4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease

4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes

5 Chapter 5: Post-Transplant Infections & Supportive Care

5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition

6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS

6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy

7 Chapter 7: Chronic GVHD & Long-Term Survivorship

7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment

8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards

8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement

3.6 Infusion Monitoring & Acute Reaction Differential Management

Key Takeaways Explain This Topic AI

Monitoring intervals during and after administration are product-specific and are documented against the product instructions; a familiar blood-component monitoring schedule is not a valid substitute.

For any reaction, pause or stop as directed, maintain access, assess airway/breathing/circulation, activate the emergency pathway, preserve the product/records, and treat the diagnosed syndrome under orders.

Differentiate allergy/anaphylaxis, hemolysis, bacterial contamination, volume overload, acute lung injury, citrate/DMSO effects, and disease- or therapy-related deterioration using timing, examination, labs, and product characteristics.

Bradycardia with flushing and nausea during a thawed cryopreserved product suggests DMSO-mediated histamine release and vagal stimulation, whereas hypertension with jugular venous distension and bibasilar crackles suggests circulatory overload from the infused volume.

Last updated: September 2026

1. Monitoring During and After Administration

Obtain the protocol-defined baseline, including symptoms, temperature, blood pressure, pulse, respiratory rate, oxygen saturation, access assessment, and other monitoring indicated by product volume, DMSO, ABO mismatch, cardiac risk, or prior reaction. Remain able to observe and respond throughout administration. Frequency may be more intensive at initiation and after each bag, but the guide does not replace the label or center's vital-sign schedule.

Watch for fever/rigors, flushing, urticaria, angioedema, wheeze/stridor, dyspnea, chest or back pain, nausea/vomiting, bradycardia or tachyarrhythmia, blood-pressure change, hypoxia, hemoglobinuria, volume overload, neurologic change, and access-site leakage. Trend cumulative volume and DMSO across bags. Post-administration observation duration is individualized to reaction, product, setting, and protocol.

2. Acute Reaction Priorities and Differential

For a severe reaction, stop or pause administration as directed, preserve the product and tubing for investigation, maintain vascular access with a compatible solution, assess airway/breathing/circulation, call the emergency and transplant/cellular team, and verify the product/patient match. Do not restart without an authorized decision.

Pattern Key clues Immediate nursing focus

Anaphylaxis Rapid airway swelling, wheeze/stridor, urticaria, hypotension Emergency response and IM epinephrine per anaphylaxis protocol; airway/oxygen/circulatory support. Antihistamine or corticosteroid is adjunctive, not a substitute for epinephrine.

DMSO-related reaction Garlic/creamed-corn odor, nausea, flushing, pressure change, bradycardia, dyspnea Pause/slow per order, supportive care, and evaluate severity; symptomatic bradycardia follows the emergency protocol.

Hemolysis/ABO reaction Fever/chills, pain, hypotension, red urine, laboratory hemolysis Stop, verify identity/compatibility, notify transfusion/cell lab, send the required specimens/product, and support kidney/hemodynamic status per orders.

Contamination/sepsis Rigors, high fever, rapidly progressive shock Cultures from patient and product as directed, immediate antimicrobial/sepsis care, and preservation/reporting of the bag and tubing.

Volume or pulmonary reaction Dyspnea/hypoxia with hypertension/overload clues or noncardiogenic pattern Stop, support oxygenation/hemodynamics, and differentiate overload, lung injury, anaphylaxis, sepsis, and cardiac disease before assuming diuresis.

Mechanical/product issue Leak, occlusion, aggregate, wrong rate, extravasation, lost product Stop manipulation, clamp/contain safely, preserve sterility, and contact the cell lab/medical director for the approved recovery or deviation process.

After any significant reaction, document timing, bag/product identifiers, volume/cells delivered, assessment, actions, response, notifications, specimens, and disposition. Complete the required institutional, manufacturer, transfusion-service, FDA, or accreditation reports as applicable.

Loading diagram... Acute Infusion Reaction Emergency Management Algorithm

3. Discriminating the Look-Alike Cardiopulmonary Emergencies

Dyspnea during or shortly after a cellular product is the situation that most often requires the nurse to reason faster than the laboratory. Several syndromes present inside the same window and are separated almost entirely by bedside findings, because confirmatory testing arrives long after the first ten minutes of care have been decided.

Transfusion-associated circulatory overload (TACO) is a hydrostatic problem: delivered volume exceeds what the circulation can accommodate. Look for hypertension , jugular venous distension, bibasilar crackles, a widened pulse pressure, and rapidly positive fluid balance. It favors recipients with cardiomyopathy, renal impairment, small body size, or a large-volume fresh marrow product, and oxygenation improves with upright positioning and ordered diuresis.

Transfusion-related acute lung injury (TRALI) is a permeability problem in the pulmonary microvasculature. Look for hypotension or an unchanged blood pressure , fever, and bilateral infiltrates without jugular venous distension or other volume-overload signs. Diuresis does not help and may harm; management is oxygenation and ventilatory support.

Anaphylaxis adds airway and skin involvement - stridor, wheeze, urticaria, angioedema - with hypotension, usually within minutes of starting. DMSO-mediated reaction produces flushing, nausea, the characteristic odor, and bradycardia rather than tachycardia, with clear lungs.

  • Discriminator TACO TRALI Anaphylaxis DMSO effect
  • Blood pressure Elevated Low or unchanged Low Either direction
  • Fever Absent Common Absent Absent
  • Jugular venous distension Present Absent Absent Absent
  • Skin or airway signs Absent Absent Prominent Flushing only
  • Heart rate Elevated Elevated Elevated Often bradycardic
  • Response to diuresis Improves No benefit or harmful No benefit Not applicable

Two habits prevent most missed reactions. First, anchor every finding to the patient's own baseline rather than to a population normal range: a rise from 96/58 to 118/70 mmHg is a meaningful change in someone who lives at the lower number, and 37.8 degrees Celsius matters in a patient who has been afebrile for a week. Second, reassess after every intervention rather than only at scheduled intervals, because a rate reduction, a position change, or a premedication dose creates a new baseline that must be measured before it can be trusted.

Volume tolerance is body-size dependent, so pediatric and small adult recipients reach a hazardous cumulative volume at a bag count that would be unremarkable in a larger patient. Track milliliters per kilogram alongside absolute volume and escalate the running total to the prescriber before the final bag rather than after the patient decompensates.

4. Post-Administration Handoff and Dose Accounting

Observation does not end when the bag empties. Before the patient leaves the monitored setting, reconcile and document three things: the total volume and DMSO delivered across all bags , the cell dose actually administered compared with the dose ordered, and any residual or lost product with its disposition. A bag that clotted, leaked, or was returned unfinished changes the delivered dose, which the transplant team needs when interpreting later engraftment kinetics or a manufacturing investigation.

Hand off the specific reaction history rather than a global "tolerated well." Name what happened, at what cumulative volume, what was given, and how the patient responded, because the next bag or the next product often reproduces the same physiology. For outpatient administration, confirm before discharge that the patient and caregiver can state which symptoms require an immediate return, who to call at any hour, and that transportation is available throughout the product-defined monitoring window.